Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

1,869JPY
10:29pm EDT
Change (% chg)

¥10 (+0.54%)
Prev Close
¥1,859
Open
¥1,873
Day's High
¥1,878
Day's Low
¥1,859
Volume
314,900
Avg. Vol
1,174,433
52-wk High
¥2,131
52-wk Low
¥1,424

Chart for

About

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of... (more)

Overall

Beta: 0.76
Market Cap(Mil.): ¥1,062,459.00
Shares Outstanding(Mil.): 576.48
Dividend: 12.50
Yield (%): 1.36

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

BRIEF- R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Aug 25 2017

BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.

* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in the U.S.

Aug 24 2017

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

Aug 03 2017

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

Apr 18 2017

BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint

* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint

Apr 06 2017

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

Mar 27 2017

Earnings vs. Estimates